209 related articles for article (PubMed ID: 19464324)
21. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
[TBL] [Abstract][Full Text] [Related]
22. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Kimura G; Kadoyama K; Brown JB; Nakamura T; Miki I; Nisiguchi K; Sakaeda T; Okuno Y
Int J Med Sci; 2015; 12(2):135-40. PubMed ID: 25589889
[TBL] [Abstract][Full Text] [Related]
23. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
McDougle CJ; Stigler KA; Erickson CA; Posey DJ
J Clin Psychiatry; 2008; 69 Suppl 4():15-20. PubMed ID: 18533764
[TBL] [Abstract][Full Text] [Related]
24. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
25. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.
Newman-Tancredi A; Assié MB; Leduc N; Ormière AM; Danty N; Cosi C
Int J Neuropsychopharmacol; 2005 Sep; 8(3):341-56. PubMed ID: 15707540
[TBL] [Abstract][Full Text] [Related]
26. The value of atypical antipsychotics in the treatment of schizophrenia.
Jessen LM
Manag Care; 2002 Jul; 11(7 Suppl):8-12; discussion 12-3. PubMed ID: 12181875
[No Abstract] [Full Text] [Related]
27. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.
Egashira N; Okuno R; Matsushita M; Abe M; Mishima K; Iwasaki K; Nishimura R; Oishi R; Fujiwara M
Eur J Pharmacol; 2008 Sep; 592(1-3):103-8. PubMed ID: 18644366
[TBL] [Abstract][Full Text] [Related]
28. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Croarkin PE; Emslie GJ; Mayes TL
J Clin Psychiatry; 2008 Jul; 69(7):1157-65. PubMed ID: 18572981
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.
Hirose T; Uwahodo Y; Yamada S; Miwa T; Kikuchi T; Kitagawa H; Burris KD; Altar CA; Nabeshima T
J Psychopharmacol; 2004 Sep; 18(3):375-83. PubMed ID: 15358981
[TBL] [Abstract][Full Text] [Related]
30. Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone.
Letmaier M; Painold A; Holl AK; Grohmann R; Vergin H
Int J Psychiatry Clin Pract; 2012 Jun; 16(2):153-6. PubMed ID: 22211772
[TBL] [Abstract][Full Text] [Related]
31. Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats.
Auclair AL; Galinier A; Besnard J; Newman-Tancredi A; Depoortère R
Psychopharmacology (Berl); 2007 Jul; 193(1):45-54. PubMed ID: 17393144
[TBL] [Abstract][Full Text] [Related]
32. Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
den Boon FS; Body S; Hampson CL; Bradshaw CM; Szabadi E; de Bruin N
J Psychopharmacol; 2012 Sep; 26(9):1231-43. PubMed ID: 21969105
[TBL] [Abstract][Full Text] [Related]
33. Atypical antipsychotics for the treatment of disruptive behavior.
Lohr WD; Honaker J
Pediatr Ann; 2013 Feb; 42(2):72-7. PubMed ID: 23379410
[No Abstract] [Full Text] [Related]
34. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
McCreary AC; Glennon JC; Ashby CR; Meltzer HY; Li Z; Reinders JH; Hesselink MB; Long SK; Herremans AH; van Stuivenberg H; Feenstra RW; Kruse CG
Neuropsychopharmacology; 2007 Jan; 32(1):78-94. PubMed ID: 16710314
[TBL] [Abstract][Full Text] [Related]
35. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
Bruins Slot LA; De Vries L; Newman-Tancredi A; Cussac D
Eur J Pharmacol; 2006 Mar; 534(1-3):63-70. PubMed ID: 16497294
[TBL] [Abstract][Full Text] [Related]
36. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Dubois D
Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418
[TBL] [Abstract][Full Text] [Related]
37. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
38. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Gogos A; Bogeski M; van den Buuse M
Behav Pharmacol; 2008 Sep; 19(5-6):548-61. PubMed ID: 18690109
[TBL] [Abstract][Full Text] [Related]
39. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
40. Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats.
Li M; Davidson P; Budin R; Kapur S; Fleming AS
Schizophr Res; 2004 Sep; 70(1):69-80. PubMed ID: 15246466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
